Literature DB >> 12892826

Effects of U50,488H on transient outward and ultra-rapid delayed rectifier K+ currents in young human atrial myocytes.

Guo-Sheng Xiao1, Jing-Jun Zhou, Yiu-Fai Cheung, Gui-Rong Li, Tak-Ming Wong.   

Abstract

The effects of trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide methanesulfonate salt (U50,488H), a selective kappa-opioid receptor agonist, on transient outward K+ current (Ito1) and ultra-rapid delayed rectifier K+ current (IKur) in young human atrial myocytes were evaluated with a whole-cell patch-clamp technique. At +10 mV, U50,488H decreased Ito1 in a concentration-dependent manner (IC50=12.4+/-3.5 microM), while at +50 mV, U50,488H produced biphasic effects on Ito1-increasing and decreasing the current at 1-3 and 10-30 microM, respectively. U50,488H at 10 microM shifted the midpoint (V0.5) of Ito1 activation in a depolarizing direction by approximately 5 mV, accelerated the inactivation, and slowed the recovery from inactivation of Ito1. In addition, U50,488H inhibited IKur in a concentration-dependent manner (IC50=3.3+/-0.6 microM). The effects of U50,488H on the two types of K+ currents were not antagonized by either 5 microM nor-binaltorphimine or 300 nM naloxone. These results indicate that U50,488H affects both Ito1 and IKur in young human atrial myocytes in an opioid receptor-independent manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892826     DOI: 10.1016/s0014-2999(03)01974-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Cardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heart.

Authors:  Liang Cheng; Sai Ma; Long-Xiao Wei; Hai-Tao Guo; Lu-Yu Huang; Hui Bi; Rong Fan; Juan Li; Ya-Li Liu; Yue-Min Wang; Xin Sun; Quan-Yu Zhang; Shi-Qiang Yu; Ding-Hua Yi; Xin-Liang Ma; Jian-Ming Pei
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

2.  A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic.

Authors:  Jeffrey J Buda; F I Carroll; Thomas R Kosten; Dennis Swearingen; Bradford B Walters
Journal:  Neuropsychopharmacology       Date:  2015-01-23       Impact factor: 7.853

Review 3.  Cardiac Potassium Channels: Physiological Insights for Targeted Therapy.

Authors:  Kamalan Jeevaratnam; Karan R Chadda; Christopher L-H Huang; A John Camm
Journal:  J Cardiovasc Pharmacol Ther       Date:  2017-09-25       Impact factor: 2.457

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.